CytoDyn (CYDY) Common Equity (2011 - 2026)

CytoDyn's Common Equity history runs 16 years deep, the most recent figure standing at -$104.3 million for Q1 2026.

• Quarterly Common Equity fell 12.16% year-over-year to -$104.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$104.3 million (down 12.16% YoY) and the FY2025 annual result came in at -$96.0 million, up 17.74% from the prior year.
• Common Equity was -$104.3 million for Q1 2026 at CytoDyn, up from -$119.7 million in the prior quarter.
• Across five years, Common Equity topped out at -$22.5 million in Q1 2022 and bottomed at -$119.7 million in Q4 2025.
• A 5-year average of -$99.9 million and a median of -$104.3 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity sank 813.43% — and 2024, when it climbed 27.1%.
• CytoDyn's Common Equity stood at -$116.0 million in 2022, then gained by 1.37% to -$114.4 million in 2023, then climbed by 21.85% to -$89.4 million in 2024, then plunged by 33.96% to -$119.7 million in 2025, then grew by 12.91% to -$104.3 million in 2026.
• Business Quant data shows CYDY's Common Equity at -$104.3 million in Q1 2026, -$119.7 million in Q4 2025, and -$99.5 million in Q3 2025.